Format

Send to

Choose Destination
Clin Endocrinol (Oxf). 2017 May;86(5):739-746. doi: 10.1111/cen.13310. Epub 2017 Mar 9.

Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome.

Author information

1
The Obstetrics and Gynecology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
2
Section of Inflammation and Cardiometabolic Disease, National Heart, Lung and Blood Institute, Bethesda, MA, USA.
3
Department of Nutritional Sciences, Penn State College of Health and Human Development, University Park, Philadelphia, PA, USA.
4
Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
5
Department of Kinesiology, Penn State College of Health and Human Development, University Park, Philadelphia, PA, USA.
6
Department of Obstetrics and Gynecology, Penn State College of Medicine, Hershey, PA, USA.
7
Department of Psychiatry, Temple University, Philadelphia, PA, USA.
8
Department of Social and Behavioral Science, Center for Obesity Research and Education, College of Public Health, Temple University, Philadelphia, PA, USA.

Abstract

OBJECTIVE:

To study the effects of oral contraceptive pills (OCP), the first-line treatment for PCOS, on high-density lipoprotein cholesterol (HDL-C) function (reverse cholesterol efflux capacity) and lipoprotein particles measured using nuclear magnetic resonance spectroscopy in obese women.

DESIGN:

Secondary analysis of a randomized controlled trial (OWL-PCOS) of OCP or Lifestyle (intensive Lifestyle modification) or Combined (OCP + Lifestyle) treatment groups for 16 weeks.

PATIENTS:

Eighty-seven overweight/obese women with PCOS at two academic centres.

MEASUREMENTS:

Change in HDL-C efflux capacity and lipoprotein particles.

RESULTS:

High-density lipoprotein cholesterol efflux capacity increased significantly at 16 weeks in the OCP group [0·11; 95% confidence interval (CI) 0·03, 0·18, P = 0·008] but not in the Lifestyle (P = 0·39) or Combined group (P = 0·18). After adjusting for HDL-C and TG levels, there was significant mean change in efflux in the Combined group (0·09; 95% CI 0·01, 0·15; P = 0·01). Change in HDL-C efflux correlated inversely with change in serum testosterone (rs = -0·21; P = 0·05). In contrast, OCP use induced an atherogenic low-density lipoprotein cholesterol (LDL-C) profile with increase in small (P = 0·006) and large LDL-particles (P = 0·002). Change in small LDL-particles correlated with change in serum testosterone (rs = -0·31, P = 0·009) and insulin sensitivity index (ISI; rs = -0·31, P = 0·02). Both Lifestyle and Combined groups did not show significant changes in the atherogenic LDL particles.

CONCLUSIONS:

Oral contraceptive pills use is associated with improved HDL-C function and a concomitant atherogenic LDL-C profile. Combination of a Lifestyle program with OCP use improved HDL-C function and mitigated adverse effects of OCP on lipoproteins. Our study provides evidence for use of OCP in overweight/obese women with PCOS when combined with Lifestyle changes.

PMID:
28199736
PMCID:
PMC5651984
DOI:
10.1111/cen.13310
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center